Multiple Sclerosis


Immune Tolerance Network Launches Cell Therapy vs. Standard of Care Clinical Trial for Multiple Sclerosis Patients

The Immune Tolerance Network (ITN) has opened the BEAT-MS clinical trial for patient enrollment. BEAT-MS or “Best Available Therapy vs. Autologous Hematopoietic Stem Cell Transplant (AHSCT) for MS” will investigate high dose immunosuppression followed by AHSCT—a type...

Swiss Biotechnology Company Anokion SA Achieves Major Acquisition and Funding, Providing Runway for Multiple Emerging Autoimmune Therapies

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the acquisition of Kanyos Bio, Inc. and the completion of a $40 million Series B financing. Anokion has come a long way, according to...

Pin It on Pinterest